A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year-old girls and boys – clinical protocol

A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year-old girls and boys – clinical protocol

Abstract Background Human papillomavirus (HPV) vaccines are indicated for the prevention of cancers and genital warts caused by vaccine-covered HPV types. Although the standard regimen requires a two or three-dose vaccine series, there is emerging data suggesting that a single dose of the bivalent o...

Full description

Bibliographic Details
Main Authors: Yi Zeng, Anna-Barbara Moscicki, Vikrant V. Sahasrabuddhe, Francisco Garcia, Heide Woo, Chiu-Hsieh Hsu, Eva Szabo, Eileen Dimond, Susan Vanzzini, Angelica Mondragon, Valerie Butler, Hillary DeRose, H.-H. Sherry Chow
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Cancer
Subjects:
Human papillomavirus
HPV vaccine
Serologic geometric mean titer
Gardasil 9
Nonavalent HPV vaccine
Cervical cancer
Online Access:http://link.springer.com/article/10.1186/s12885-019-5444-4

Internet

http://link.springer.com/article/10.1186/s12885-019-5444-4

Similar Items